EY6A

SARS-CoV-2-neutralising antibody

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Link	Tested on	Impact factor	Notes	Publication date
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient Preprint Antibody	VERO E6 cell cultures			Jun/13/2020

Link	Publication date
Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction.	Jan/16/2022